Dr. Lal Path Labs · NSE: LALPATHLAB · BSE: 539524
Q2 FY21 results · Jul–Sep 2020
Dr. Lal Path Labs reported revenue from operations of ₹431.90 crore (up 18.1% from Q2 FY20) and net profit of ₹87.10 crore (up 7.5% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 431.90 | 365.60 | +18.1% | 266.00 | +62.4% |
| Other income | 12.90 | 14.80 | −12.8% | 11.40 | +13.2% |
| Total income | 444.80 | 380.40 | +16.9% | 277.40 | +60.3% |
| Profit before tax | 116.60 | 102.30 | +14.0% | 38.10 | +206.0% |
| Net profit for the period | 87.10 | 81.00 | +7.5% | 28.40 | +206.7% |
| Attributable to shareholders of the company | 85.30 | 80.50 | +6.0% | 28.40 | +200.4% |
| EPS, basic (₹) | 10.34 | 9.77 | +5.8% | 3.45 | +199.7% |
| Net margin (%) | 20.2 | 22.2 | 10.7 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 404.30 | 351.20 | +15.1% | 255.00 | +58.5% |
| Other income | 12.50 | 16.20 | −22.8% | 11.10 | +12.6% |
| Total income | 416.80 | 367.40 | +13.4% | 266.10 | +56.6% |
| Profit before tax | 106.80 | 99.80 | +7.0% | 38.50 | +177.4% |
| Net profit for the period | 79.90 | 79.50 | +0.5% | 28.80 | +177.4% |
| EPS, basic (₹) | 9.68 | 9.65 | +0.3% | 3.50 | +176.6% |
| Net margin (%) | 19.8 | 22.6 | 11.3 |
Consolidated
- Filed with BSE
- 06 Nov 2020, 18:42 IST
- Board meeting
- 06 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Nov 2020, 18:42 IST
- Board meeting
- 06 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE